Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB315 in Advanced Solid Tumors Expressing Claudin18.2
NCT05367635Phase 1Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Mar 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of lucansatuzumab in solid tumor, gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Kelun-Biotech. Primary endpoints: Dose Limiting Toxicities at 28 days and Objective Response Rate up to 2 years. Started Mar 2022; status: recruiting.
02
Drugs
lucansatuzumab
03
Conditions
solid tumorgastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05367635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367635.